As filed with the Securities and Exchange Commission on February 4, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Generate Biomedicines, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 83-1630228 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 101 South Street, Suite 900 Somerville, MA 02143 (8 ...

Core Viewpoint - The current rotation within ARK Invest indicates a strong belief that 2026 will be a pivotal year for the genomic revolution [1] Group 1: Investment Strategy - ARK Invest is significantly reducing its holdings in legacy winners like Tesla and Rocket Lab to invest millions in gene-editing companies [2] - The firm is focusing on acquiring shares of CRISPR Therapeutics, Intellia Therapeutics, Beam Therapeutics, and Pacific Biosciences as 2025 ends [3] Group 2: Thematic Focus - Cathie Wood's investment thesis combines artificial intelligence with programmable biology, emphasizing AI's transformative potential in healthcare [4] - The multiomics flywheel framework suggests that AI enhances all aspects of multiomics, from biological data generation to disease diagnosis and drug development [4] Group 3: Technological Advancements - Improved algorithms are making gene sequencing faster, while cheaper sequencing provides more data for AI learning, leading to breakthroughs in gene editing and new treatment possibilities [5] Group 4: Holdings Overview - By late December 2025, ARK increased its stake in CRISPR Therapeutics to over 5% of the ARKK Innovation Fund, with Beam Therapeutics at 3.41%, Twist at 2%, and Intellia at 1.14% [6] - ARK also manages the Ark Genomic Revolution Fund, which invests in companies across healthcare and information technology relevant to the genomics theme [6]